Covid cases are rising as omicron’s ‘stealth’ subvariant spreads around the world

Covid cases are rising as omicron’s ‘stealth’ subvariant spreads around the world


LONDON — Covid cases are rising in Europe, with an increasing number being attributed to the prevalence of a “stealth” subvariant of the omicron strain.

Covid cases have increased dramatically in the U.K. in recent weeks, while Germany continues to mark record high daily infections with more than 250,000 new cases a day. Elsewhere, France, Switzerland, Italy and the Netherlands are also seeing Covid infections start to rise again, aided and abetted by the relaxation of coronavirus measures and the spread of a new subvariant of omicron, known as BA.2.

Public health officials and scientists are closely monitoring BA.2, which has been described as a “stealth” variant because it has genetic mutations that could make it harder to distinguish from the delta variant using PCR tests, compared with the original omicron variant, BA.1.

A doctor monitors a Covid-19 patient in the Covid-19 intensive care unit of the community hospital in Germany on April 28, 2021.

RONNY HARTMANN | AFP | Getty Images

The new subvariant would be the latest in a long line to emerge since the pandemic began in China in late 2019. The omicron variant — the most transmissible strain so far — overtook the delta variant, which itself supplanted the alpha variant — and even this was not the original strain of the virus.

Now, Danish scientists believe that the BA.2 subvariant is 1½ times more transmissible than the original omicron strain, and is already overtaking it. The BA.2 variant is now responsible for over half of the new cases in Germany and makes up around 11% of cases in the U.S.

That number is expected to rise further, as it has in Europe.

“It’s clear that BA.2 is more transmissible than BA.1 and this, combined with the relaxation of mitigation measures and waning immunity, is contributing to the current surge in infections,” Lawrence Young, a professor of molecular oncology at Warwick University, told CNBC on Monday.

“The increased infectiousness of BA.2 is already out-competing and replacing BA.1, and we are likely to see similar waves of infection as other variants enter the population.”

As long as the virus continues to spread and replicate, particularly in populations which are undervaccinated or where vaccine-induced immunity is decaying, “it will throw up new variants and these will remain a continual threat even to those countries with high rates of vaccination,” Young noted. “Living safely with Covid doesn’t mean ignoring the virus and hoping it will go away forever.”

What do we know about BA.2?

The UKHSA has done a preliminary analysis comparing vaccine effectiveness against symptomatic disease for BA.1 and BA.2 infections and found that the levels of protection are similar, with efficacy of up to 77% soon after a booster shot, although this wanes over time.

‘Growth advantage’

The WHO has also noted that BA.2 differs from BA.1 in its genetic sequence, including some amino acid differences in the spike protein and other proteins which could give it an advantage over the original omicron.

“Studies are ongoing to understand the reasons for this growth advantage, but initial data suggest that BA.2 appears inherently more transmissible than BA.1, which currently remains the most common omicron sublineage reported. This difference in transmissibility appears to be much smaller than, for example, the difference between BA.1 and Delta,” the organization said last month.

The WHO added that initial studies suggest that anyone who has been infected with the original omicron variant has strong protection against reinfection with its subvariant BA.2.

Dr. Andrew Freedman, an academic covering infectious disease at Cardiff Medical School, told CNBC he doesn’t think we need to be too concerned about BA.2, despite the fact that it is slightly more contagious.

“I suspect the rising number of cases is related to several factors including BA.2, the relaxation of restrictions and more social mixing, less mask wearing and some waning of immunity from both previous infections and vaccination, especially in those who received boosters early on,” he said.

“There has been an upturn in hospital admissions testing positive for Covid in the U.K., but many of these are incidental and there has not been a parallel increase in deaths.”

Growing in prevalence

The U.K., and the rest of Europe, have acted as a bellwether for the U.S. at several points in the pandemic, declared two years ago by the WHO. particularly when it comes to the rise and spread of new Covid variants which have emerged and subsequently supplanted previous strains of the virus.

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:

It’s unclear whether BA.2 is contributing to the latest wave of cases, although a prominent infectious disease expert in China told news outlet Caixin that much of the current outbreak is being driven by the BA.2 subvariant.

U.K. data certainly illustrates BA.2’s increasingly prevalence. Sequenced data from Feb. 27 to March 6 found that 68.6% of cases were omicron lineage BA.2, with just 31.1% omicron BA.1.



Source

Abortion pill makers brace for restrictions a year after Trump’s election
Health

Abortion pill makers brace for restrictions a year after Trump’s election

Mifepristone and Misoprostol pills are pictured Wednesday, Oct. 3, 2018, in Skokie, Illinois. Erin Hooley | Chicago Tribune | Tribune News Service | Getty Images Just over a year since Donald Trump was elected president again, the $6.9 billion abortion pill industry is operating under the same federal rules he inherited from former President Joe […]

Read More
Republicans push Obamacare tax credit alternatives as enrollment deadline looms
Health

Republicans push Obamacare tax credit alternatives as enrollment deadline looms

An Obamacare sign is displayed outside an insurance agency on Nov. 12, 2025 in Miami, Florida. Joe Raedle | Getty Images With enhanced Obamacare tax credits set to expire at the end of the year, Republicans are proposing new alternatives aimed at lowering the cost of health care. Their window for doing so is rapidly […]

Read More
Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target
Health

Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target

The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg | Getty Images Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal. The trial tested whether semaglutide — the […]

Read More